gene therapy

R&D

Partner Content

4th Gene Therapy Analytical Development Europe Summit 2023

2-4 May, 2023 London, UK Actionable Insights to Optimise Analytical Development for Gene Therapy Products

News

4DMT's Fabry gene therapy on hold, but 'remains active'

4D Molecular Therapeutics (4DMT) has said a trial of its gene therapy for Fabry disease has been placed on a clinical hold by the FDA, a few weeks after it reported three

News

BioMarin gets first access deal in EU for gene therapy Rocta...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA) r

News

Astellas licenses companion drug for Pompe gene therapy

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe

News

Free access to Zolgensma curbed, says Novartis

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company.

News